Overview

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

This is a study to test if a new higher dose of Copaxone is more effective in treating relapsing-remitting multiple sclerosis than the currently available 20 mg dose.

Phase:

Phase 2

Details

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries

Treatments:

(T,G)-A-L
Glatiramer Acetate